Replies to post #4223 on Ayala Pharmaceuticals Inc (ADXS)

[hdwrsft]

James, July 2nd, 2014 ---".....today announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the treatment of canine osteosarcoma and other cancers. While the USDA has no specific obligation to respond within a prescribed timeframe, Aratana anticipates that responses from the USDA to the filing will occur over the next 12 to 18 months." -- TheStreet article



Hmm, IF we're extremely lucky, we could receive USDA approval at any time, even by the end of the week:

"While the USDA has no specific obligation to respond within a prescribed timeframe...."


My other observation is that they used the words "....and other cancers".....

"......for the treatment of canine osteosarcoma and other cancers."

Once AT-014 is commercialized, is it meant to be approved for and to target "other" cancers as well as Canine Osteosarcoma?? Does that mean we are limiting ourselves by thinking that the only market is for the treatment of Canine Osteosarcoma??

For AT-014, what and how many "other" cancers will be approved by the USDA to treat??

If the market is going to be beyond CO,

That's a question to ask PETX.

[CATTDOGG12347]

Looking forward to hearing something on that